Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(25)
•••
Comment by Blazesbon Aug 17, 2020 7:53pm
277 Views
Post# 31420469

RE:RE:RE:RE:Hiring Stern

RE:RE:RE:RE:Hiring Stern
Howsitgoing2020 wrote: You're referencing that the trial allowed patients to simultaneously dose with acetaminophen at their own discretion right? Which in turn caused the higher liver enzymes in some. I'm sure big pharma is aware of this and reasonable determine how much Atb-346 vs acetaminophen caused the liver enzyme increase. If Atb-346 was the sole cause, don't you think all patients would have had increased liver enzymes and not just a smaller sample that also took acetaminophen? 

What you and i think doesn't matter.  What does matter is that until the first phase 3 is completed the acetaminophen issue remains.

The acetaminophin 'signifigance' caused the $29 million cash raise to be priced at 0.40 per share when the market price was over .70.   Antibe management sold 1/4 of the company at .40 per share.  That price had the acetaminophin 'signifigance' baked in.

Until the first level of phase 3 is completed the acetaminophin issue remains. More to the point the stock will trade around the .40 cent mark--right where Dan Legault thinks it's worth. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities